Synapse - Alison Schram

Results (122)

PYNNACLE phase II assessing rezatapopt in patients with advanced solid tumors, including lung cancer, harboring a TP53 Y220C mutation

Meeting Abstract

De Miguel, M. J.; Dumbrava, E. E.; Body, A.; Eberst, L.; Frenel, J. S.; Italiano, A.; Johnson, M. L.; Kaczmar, J.; Kummar, S.; Lorusso, P. M.; more...
Journal of Thoracic Oncology (2025)

Fulltext@MSK | Save

Retrospective analysis of BRCA-altered uterine sarcoma treated with poly(ADP-ribose) polymerase inhibitors

Journal Article

Rao, M.; Merrill, M.; Troxel, M.; Chiang, S.; Momeni-Boroujeni, A.; Hensley, M. L.; Schram, A. M.
JCO Precision Oncology (2025)

Fulltext@MSK | Save

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors

Journal Article

Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
ESMO Open (2025)

Fulltext@MSK | Save

Efficacy of zenocutuzumab in NRG1 fusion-positive cancer

Journal Article

Schram, A. M.; Goto, K.; Kim, D. W.; Macarulla, T.; Hollebecque, A.; O'Reilly, E. M.; Ou, S. H. I.; Rodon, J.; Rha, S. Y.; Nishino, K.; more...
New England Journal of Medicine (2025)

Fulltext@MSK | Save

PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation

Meeting Abstract

Schram, A. M.; Lopes, G.; El-Khoueiry, A. B.; Fontana, E.; Karasic, T. B.; Kummar, S.; Lorusso, P.; Gregorc, V.; Millward, M.; Aix, S. P.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation

Meeting Abstract

Schram, A.; Shapiro, G.; Thompson, J.; Vandross, A.; Kummar, S.; El-Khoueiry, A.; LeDuke, K.; Fellous, M.; Alland, L.; Dumbrava, E.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)

Meeting Abstract

Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)

Meeting Abstract

Højgaard, M.; Yap, T. A.; Lee, E. K.; Weiss, M. C.; Lheureux, S.; Simpkins, F.; LoRusso, P.; Carneiro, B. A.; Moy, R. H.; Aguado-Fraile, E.; more...
European Journal of Cancer (2024)

Fulltext@MSK | Save

Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): The ReFocus study